Please assess the completion status of the following clinical trial:

Trial Title: Study of NPO-11 in Patients Undergoing Gastrointestinal Endoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients who are capable of understanding and complying with protocol requirements in the opinion of the investigator or the sub-investigator.~2. Patients who are able to fill in the informed consent form.~3. Patients who require gastrointestinal endoscopy using a scope of 9mm or greater diameter for follow-up of confirmed or investigation of a suspected upper gastrointestinal disease. (except for transnasal endoscopy and emergency endoscopy)~4. Male or female chinese patients aged _18_ to _80~5. Patients who agree to use routinely adequate contraception from signing of informed consent to follow-up.~Exclusion Criteria:~1. Patients have received any investigational drug of other study within 120 days prior to providing their informed consent.~2. Patients had been administered NPO-11 in the past.~3. Patients who are the study site investigator or sub-investigator, an immediate family member (eg, spouse,parent, child, sibling), or may consent under duress.~4. Patients have a history of upper gastrointestinal tract surgery.~5. Patients have gastric stenosis or deformity that would make observation of peristaltic movement difficult.~6. Patients have bleeding in the upper gastrointestinal tract and require hemostatic intervention.~7. Patients have reflux esophagitis (defined as Los Angeles Class: B, C or D)~8. Patients have an active gastric or duodenal ulcer (defined as Sakita-Miwa class: A1 or A2)~9. Patients are on treatment (radiotherapy or chemotherapy) for cancer.~10. Patient have decreased heart function (NYHA heart function class: III or more)~11. Patients have a history of shock, hypersensitivity or allergies to l-menthol or peppermint oil.~12. Patients have a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within 12 months prior to the screening visit.~13. Patients are required to take excluded medications.~14. If female, patients are pregnant or lactating or intending to become pregnant from signing of informed consent to follow-up.~15. Any subject who, in the opinion of the investigator or the sub-investigator, is unable to comply with the requirements of the study or is unsuitable for any reason.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- NPO-11 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).